These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8832017)

  • 1. Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy.
    Toren A; Ackerstein A; Gazit D; Or R; Raveh D; Kupolovicz U; Engelhard D; Nagler A
    Bone Marrow Transplant; 1996 Jul; 18(1):209-10. PubMed ID: 8832017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT.
    Klapholz L; Ackerstein A; Goldenhersh MA; Vardy D; Nagler A
    Bone Marrow Transplant; 1993 Jun; 11(6):443-6. PubMed ID: 8334424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT).
    Toren A; Or R; Ackerstein A; Nagler A
    Bone Marrow Transplant; 1997 Jul; 20(1):67-9. PubMed ID: 9232260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
    Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
    Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
    Tiberghien P; Racadot E; Fest T; Lioure B; Pariset J; Delain M; Voillat L; Flesch M; Amsallem D; Plouvier E
    Bone Marrow Transplant; 1991; 7 Suppl 2():145. PubMed ID: 1878686
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
    Re D; Bamborschke S; Feiden W; Schröder R; Lehrke R; Diehl V; Tesch H
    Bone Marrow Transplant; 1999 Feb; 23(3):295-8. PubMed ID: 10084263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer.
    Meehan KR; Arun B; Gehan EA; Berberian B; Sulica V; Areman EM; Mazumder A; Lippman ME
    Bone Marrow Transplant; 1999 Apr; 23(7):667-73. PubMed ID: 10218842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
    López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
    Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
    Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
    Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous hypersensitivity to co-trimoxazole after autologus bone marrow transplantation and immunotherapy with interferon alpha-2A and interleukin-2.
    Mehta J; Nagler A; Ackerstein A; Kapelushnik J; Or R
    J Assoc Physicians India; 1993 Apr; 41(4):235-6. PubMed ID: 8270579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2-based immunotherapy post-autologous blood stem cell transplantation (ABSCT).
    Nagler A; Nagler R; Ackerstein A; Levi S; Marmary Y
    Bone Marrow Transplant; 1997 Oct; 20(7):575-80. PubMed ID: 9337059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tuberculous ulcer of the tongue: clinical case].
    Ladron de Guevara R
    Odontol Chil; 1989 Dec; 37(2):277-9. PubMed ID: 2641965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with interleukin-2 (IL-2) and interferon (IFN(alpha 2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse.
    Vivancos P; Grañena A; Sarrá J; Grañena A
    Bone Marrow Transplant; 1999 Jan; 23(2):169-72. PubMed ID: 10197803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomembraneous clostridium after autologous bone marrow transplantation.
    Kavan P; Sochor M; Nyc O; Lochmann O; Koutecky J; Skala PJ; McClain LK
    Bone Marrow Transplant; 1998 Mar; 21(5):521-3. PubMed ID: 9535046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.